27677546|t|Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on omega-3 supplementation.
27677546|a|Monocyte/macrophages of patients with mild cognitive impairment (MCI) and Alzheimer disease (AD) are defective in phagocytosis and degradation amyloid beta1-42 (Abeta1-42), but are improved by omega-3 fatty acids (omega-3s). The hypothesis of this study was that active Abeta1-42 phagocytosis by macrophages prevents brain amyloidosis and thus maintains cognition. We studied the effects of self-supplementation with a drink with omega-3s, antioxidants, and resveratrol on Mini-Mental State Examination (MMSE) scores, macrophage M1M2 phenotype [the ratio of inflammatory cluster of differentiation (CD)54+CD80 and proresolution markers CD163+CD206], and Abeta1-42 phagocytosis in patients initially diagnosed as having MCI or subjective cognitive impairment (SCI). At baseline, the median MMSE score in patients in both the apolipoprotein E (ApoE) epsilon3/epsilon3 and ApoE epsilon3/epsilon4 groups was 26.0 and macrophage Abeta1-42 phagocytosis was defective. The MMSE rate of change increased in the ApoE epsilon3/epsilon3 group a median 2.2 points per year (P = 0.015 compared to 0) but did not change in the ApoE epsilon3/epsilon4 group (P = 0.014 between groups). In the ApoE epsilon3/epsilon3 group, all patients remained cognitively stable or improved; in the ApoE epsilon3/epsilon4 group, 1 recovered from dementia, but 3 lapsed into dementia. The macrophage phenotype polarized in patients bearing ApoE epsilon3/epsilon3 to an intermediate (green zone) M1-M2 type at the rate of 0.226 U/yr, whereas in patients bearing ApoE epsilon3/epsilon4, polarization was negative (P = 0.08 between groups). The baseline M1M2 type in the extreme M1 (red zone) or M2 (white zone) was unfavorable for cognitive outcome. Abeta1-42 phagocytosis increased in both ApoE groups (P = 0.03 in each groups). In vitro, the lipidic mediator resolvin D1 (RvD1) down regulated the M1 type in patients with ApoE epsilon3/epsilon3 but in some patients with epsilon3/epsilon4, paradoxically up-regulated the M1 type. Antioxidant/omega-3/resveratrol supplementation was associated with favorable immune and cognitive responses in ApoE epsilon3/epsilon3 and individual patients bearing ApoE epsilon3/epsilon4, and brings into personalized clinical practice the immune benefits expected from omega-3 mediators called resolvins. The validity of this study is limited by its small size and uncontrolled design.-Famenini, S., Rigali, E. A., Olivera-Perez, H. M., Dang, J., Chang, M T., Halder, R., Rao, R. V., Pellegrini, M., Porter, V., Bredesen, D., Fiala, M. Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on omega-3 supplementation.
27677546	84	104	cognitive impairment	Disease	MESH:D003072
27677546	105	113	patients	Species	9606
27677546	117	124	omega-3	Chemical	MESH:D015525
27677546	166	174	patients	Species	9606
27677546	185	205	cognitive impairment	Disease	MESH:D003072
27677546	207	210	MCI	Disease	MESH:D060825
27677546	216	233	Alzheimer disease	Disease	MESH:D000544
27677546	235	237	AD	Disease	MESH:D000544
27677546	335	354	omega-3 fatty acids	Chemical	MESH:D015525
27677546	356	364	omega-3s	Chemical	MESH:D015525
27677546	459	476	brain amyloidosis	Disease	MESH:D000686
27677546	572	580	omega-3s	Chemical	MESH:D015525
27677546	600	611	resveratrol	Chemical	MESH:D000077185
27677546	700	712	inflammatory	Disease	MESH:D007249
27677546	740	746	(CD)54	Gene	3383
27677546	747	751	CD80	Gene	941
27677546	778	783	CD163	Gene	9332
27677546	784	789	CD206	Gene	4360
27677546	822	830	patients	Species	9606
27677546	861	864	MCI	Disease	MESH:D060825
27677546	879	899	cognitive impairment	Disease	MESH:D003072
27677546	901	904	SCI	Disease	MESH:D003072
27677546	945	953	patients	Species	9606
27677546	966	982	apolipoprotein E	Gene	348
27677546	984	988	ApoE	Gene	348
27677546	1012	1016	ApoE	Gene	348
27677546	1145	1149	ApoE	Gene	348
27677546	1255	1259	ApoE	Gene	348
27677546	1319	1323	ApoE	Gene	348
27677546	1353	1361	patients	Species	9606
27677546	1410	1414	ApoE	Gene	348
27677546	1457	1465	dementia	Disease	MESH:D003704
27677546	1485	1493	dementia	Disease	MESH:D003704
27677546	1533	1541	patients	Species	9606
27677546	1550	1554	ApoE	Gene	348
27677546	1654	1662	patients	Species	9606
27677546	1671	1675	ApoE	Gene	348
27677546	1899	1903	ApoE	Gene	348
27677546	1969	1980	resolvin D1	Chemical	MESH:C518399
27677546	1982	1986	RvD1	Chemical	MESH:C518399
27677546	2018	2026	patients	Species	9606
27677546	2032	2036	ApoE	Gene	348
27677546	2067	2075	patients	Species	9606
27677546	2152	2160	omega-3/	Chemical	MESH:D015525
27677546	2160	2171	resveratrol	Chemical	MESH:D000077185
27677546	2252	2256	ApoE	Gene	348
27677546	2290	2298	patients	Species	9606
27677546	2307	2311	ApoE	Gene	348
27677546	2412	2429	omega-3 mediators	Chemical	-
27677546	2437	2446	resolvins	Chemical	-
27677546	2763	2783	cognitive impairment	Disease	MESH:D003072
27677546	2784	2792	patients	Species	9606
27677546	2796	2803	omega-3	Chemical	MESH:D015525
27677546	Negative_Correlation	MESH:D015525	MESH:D003072
27677546	Association	MESH:D003704	348
27677546	Association	MESH:C518399	MESH:D015525
27677546	Negative_Correlation	MESH:D015525	MESH:D060825
27677546	Negative_Correlation	MESH:D015525	MESH:D000544

